BioCardia, Inc. (BCDA)
Total Valuation
BioCardia has a market cap or net worth of $10.86 million. The enterprise value is $11.07 million.
Market Cap | 10.86M |
Enterprise Value | 11.07M |
Important Dates
The last earnings date was Wednesday, March 27, 2024, before market open.
Earnings Date | Mar 27, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
BioCardia has 25.91 million shares outstanding. The number of shares has increased by 19.52% in one year.
Shares Outstanding | 25.91M |
Shares Change (YoY) | +19.52% |
Shares Change (QoQ) | +4.21% |
Owned by Insiders (%) | 36.24% |
Owned by Institutions (%) | 8.04% |
Float | 14.61M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 22.77 |
Forward PS | n/a |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 23.21 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.41
Current Ratio | 0.41 |
Quick Ratio | 0.32 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -3,638.70%.
Return on Equity (ROE) | -3,638.70% |
Return on Assets (ROA) | -228.60% |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | $15,900 |
Profits Per Employee | -$385,700 |
Employee Count | 30 |
Asset Turnover | 0.09 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.04% in the last 52 weeks. The beta is 1.50, so BioCardia's price volatility has been higher than the market average.
Beta (1Y) | 1.50 |
52-Week Price Change | -80.04% |
50-Day Moving Average | 0.44 |
200-Day Moving Average | 0.84 |
Relative Strength Index (RSI) | 47.80 |
Average Volume (30 Days) | 391,468 |
Short Selling Information
The latest short interest is 1.01 million, so 3.91% of the outstanding shares have been sold short.
Short Interest | 1.01M |
Short Previous Month | 98,275 |
Short % of Shares Out | 3.91% |
Short % of Float | 6.94% |
Short Ratio (days to cover) | 0.32 |
Income Statement
In the last 12 months, BioCardia had revenue of $477,000 and -$11.57 million in losses. Loss per share was -$0.55.
Revenue | 477,000 |
Gross Profit | 477,000 |
Operating Income | -11.64M |
Pretax Income | -11.57M |
Net Income | -11.57M |
EBITDA | -11.16M |
EBIT | -11.57M |
Loss Per Share | -$0.55 |
Balance Sheet
The company has $1.10 million in cash and $1.32 million in debt, giving a net cash position of -$212,000 or -$0.01 per share.
Cash & Cash Equivalents | 1.10M |
Total Debt | 1.32M |
Net Cash | -212,000 |
Net Cash Per Share | -$0.01 |
Equity / Book Value | -1.60M |
Book Value Per Share | -0.06 |
Working Capital | -2.15M |
Cash Flow
In the last 12 months, operating cash flow was -$9.97 million and capital expenditures -$12,000, giving a free cash flow of -$9.99 million.
Operating Cash Flow | -9.97M |
Capital Expenditures | -12,000 |
Free Cash Flow | -9.99M |
FCF Per Share | -$0.47 |
Margins
Gross margin is 100.00%, with operating and profit margins of -2,441.09% and -2,425.79%.
Gross Margin | 100.00% |
Operating Margin | -2,441.09% |
Pretax Margin | -2,425.79% |
Profit Margin | -2,425.79% |
EBITDA Margin | -2,339.62% |
EBIT Margin | -2,425.79% |
FCF Margin | -2,093.50% |
Dividends & Yields
BioCardia does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -19.52% |
Shareholder Yield | -19.52% |
Earnings Yield | -106.54% |
FCF Yield | -91.95% |
Analyst Forecast
The average price target for BioCardia is $4.00, which is 863.86% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $4.00 |
Price Target Difference | 863.86% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | 87.39% |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on June 6, 2019. It was a reverse split with a ratio of 1:9.
Last Split Date | Jun 6, 2019 |
Split Type | Reverse |
Split Ratio | 1:9 |
Scores
BioCardia has an Altman Z-Score of -83.39 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -83.39 |
Piotroski F-Score | 2 |